| Literature DB >> 34104121 |
Saber Hassan1, Rohit Samuel1, Andrew Starovoytov1, Carolyn Lee1, Eve Aymong1, Jacqueline Saw1.
Abstract
OBJECTIVES: To compare outcomes of percutaneous coronary intervention (PCI) in spontaneous coronary artery dissection (SCAD) patients versus conservative therapy.Entities:
Mesh:
Year: 2021 PMID: 34104121 PMCID: PMC8143895 DOI: 10.1155/2021/6686230
Source DB: PubMed Journal: J Interv Cardiol ISSN: 0896-4327 Impact factor: 2.279
Figure 1(a) Type 2A SCAD of the proximal to distal RCA. (b) Successful stenting of the proximal to distal RCA with final TIMI 3 flow.
Figure 2(a) Type 2B SCAD of the mid to apical LAD. (b) Partial successful PCI of the mid to apical LAD with final TIMI 3 flow.
Figure 3(a) Type 2A SCAD of the mid to distal LAD. (b) Unsuccessful PCI with occluded distal LAD and final TIMI 0 flow.
Baseline and hospital characteristics.
| Mean ± SD, median (Q1, Q3), or | PCI ( | No PCI ( |
|
|---|---|---|---|
| Age | 48.9 ± 10.1 | 53.1 ± 9.6 | 0.001 |
| Female | 71 (94.7) | 297 (90.5) | 0.363 |
| BMI | 22.7(20.7, 26.4) | 24.7 (21.5, 28.8) | 0.016 |
|
| 0.890 | ||
| Caucasian | 63 (84.0) | 271 (82.6) | |
| East Asian | 8 (10.7) | 34 (10.4) | |
| South Asian | 3 (4.0) | 16 (4.9) | |
| African Canadian | 1 (1.3) | 2 (0.6) | |
| First Nation | 0 (0) | 3 (0.9) | |
| Family history of CAD | 23 (30.7) | 114 (34.8) | 0.589 |
| HTN | 19 (25.3) | 127 (38.7) | 0.033 |
| Hyperlipidemia | 20 (26.7) | 81 (24.7) | 0.768 |
| DM | 3 (4.0) | 13 (4.0) | >0.9 |
| Current smoker | 8 (10.7) | 34 (10.4) | 0.892 |
| Previous MI | 2 (2.7) | 16 (4.9) | 0.545 |
| History of CVA | 4 (5.3) | 11 (3.4) | 0.495 |
| Depression | 17 (22.7) | 74 (22.6) | >0.9 |
| Anxiety | 12 (16.2) | 44 (13.4) | 0.577 |
|
| |||
| Precipitating/predisposing factors | |||
| Emotional stress | 36 (48.0) | 179 (54.6) | 0.31 |
| Physical stress | 21 (28.0) | 89 (27.1) | 0.89 |
| Isometric >50 pounds | 6 (28.6) | 32 (36.0) | 0.62 |
| Connective tissue disease | 6 (8.0) | 13 (4.0) | 0.13 |
| Systemic inflammation | 6 (8.0) | 15 (4.6) | 0.25 |
| Active hormonal treatment | 14 (18.7) | 34 (10.4) | 0.073 |
| Postmenopausal | 36/71 (50.7) | 201/297 (67.7) | 0.009 |
| Peripartum | 3/71 (4.2) | 6/297 (2.0) | 0.38 |
| Fibromuscular dysplasia | 35 (46.7) | 210 (64.0) | 0.008 |
|
| |||
| Hospital presentation | |||
| STEMI | 38 (50.7) | 65 (19.8) | <0.001 |
| NSTEMI | 37 (49.3) | 263 (80.2) | <0.001 |
| Peak trop I (median, IQR) | 16.0 (3.2, 40.2) | 6.1 (1.8, 15.1) | 0.001 |
| Peak high-sensitive trop T | 990 (269, 5507) | 572 (263, 1916) | 0.399 |
| VT/VF | 10 (13.3) | 28 (8.6) | 0.272 |
| EF (%) | 50 (40, 50) | 58 (50, 63) | <0.001 |
| EF <50% | 25 (40.3) | 45 (18.1) | 0.001 |
| Hospital length of stay (days) | 3 [ | 3 [ | 0.038 |
Angiographic characteristics.
|
| PCI ( | No PCI ( |
|
|---|---|---|---|
| TIMI flow | |||
| 0 | 19 (25.3) | 54 (16.5) | 0.10 |
| 1 | 18 (24.0) | 40 (12.2) | 0.016 |
| 2 | 13 (17.3) | 45 (13.7) | 0.46 |
| 3 | 25 (33.3) | 189 (57.6) | <0.001 |
| TIMI 0 or 1 | 37 (49.3) | 94 (28.7) | 0.001 |
|
| |||
| SCAD type | |||
| Type 1 | 28 (37.3) | 84 (25.6) | 0.046 |
| Type 2 | 43 (57.3) | 227 (69.2) | 0.057 |
| Type 2A | 44.4% | 45.5% | >0.9 |
| Type 2B | 55.6% | 54.5% | >0.9 |
| Type 3 | 4 (5.3) | 17 (5.2) | >0.9 |
| Lesion length (mm) | 49 (30, 70.6) | 39.3 (27.4, 56.2) | 0.038 |
| Lesion stenosis (%) | 90.4 (70.5, 100) | 77.6 (61.4, 100) | 0.001 |
| Stenosis severity 90–100% | 39 (57.4) | 108 (34.3) | 0.001 |
| Reference artery diameter (mm) | 2.8 (2.4, 3.3) | 2.2 (1.9, 2.6) | <0.001 |
| LM involvement | 4 (5.3) | 0 (0) | 0.001 |
| LAD territory | 44 (58.7) | 154 (47.0) | 0.074 |
| LCX territory | 19 (25.3) | 112 (34.1) | 0.17 |
| RCA territory | 14 (18.7) | 91 (27.7) | 0.11 |
| LM or proximal segment | 19 (25.3) | 15 (4.6) | <0.001 |
| Multivessel noncontiguous SCAD | 10 (13.3) | 30 (9.1) | 0.28 |
Rationale for PCI.
|
| PCI |
|---|---|
| Planned PCI as an initial strategy | 60 (80.0) |
| PCI after failed med | 11 (14.6) |
| PCI after failed thrombolysis | 4 (5.3) |
| Indications for PCI | |
| Ongoing ischemia | 28 (37.3) |
| Ongoing symptoms | 19 (25.3) |
| VT or VF | 7 (9.3) |
| Hemodynamic instability | 3 (4.0) |
| LM dissection | 4 (5.3) |
| Large artery ³3 mm | 14 (18.7) |
| Proximal segments | 19 (25.3) |
| Severe stenosis (90-100%) | 25 (33.3) |
| TIMI 0 or 1 flow | 37 (49.3) |
| Multivessel SCAD | 4 (5.3) |
| Catheter-induced dissection | 7 (9.3) |
| Other | 6 (8.0) |
PCI procedural details and outcomes.
| N (%), mean ± SD | Overall | Successful | Partial success | Unsuccessful |
|---|---|---|---|---|
| Procedures | ||||
| Wiring only | 8 (10.7) | 0 (0) | 0 (0) | 8 (38.1) |
| Balloon only | 12 [ | 1 (3.8) | 3 (10.7) | 8 (38.1) |
| Cutting balloon | 1 (1.3) | 1 (3.8) | 0 (0) | 0 (0) |
| Stent | 55 (73.3) | 25 (96.2) | 25 (89.3) | 5 (23.8) |
| Unplanned stents | 22 (40.0) | 9 (36.0) | 12 (48.0) | 1 (20.0) |
| Mean number of stents | 2.6 ± 1.8 | 2.6 ± 1.4 | 2.8 ± 2.2 | 1.4 ± 0.5 |
| >3 stents used | 11 [ | 5 [ | 6 (24) | 0 (0) |
| Propagation of dissection | 33 (44.0) | 10 (38.5) | 14 (50.0) | 9 (42.9) |
| Residual dissection | 44 (58.7) | 0 (0) | 24 (86.7) | 20 (95.2) |
| Bailout emergency CABG | 4 (5.3) | 0 (0) | 1 (3.6) | 3 (14.3) |
| Stent thrombosis/closure | 4 (5.3) | 0 (0) | 2 (7.1) | 2 (9.5) |
|
| ||||
| Final TIMI flow | ||||
| 0 | 11 (14.7) | 0 (0) | 0 (0) | 11 (52.4) |
| 1 | 6 (8.0) | 0 (0) | 0 (0) | 6 (28.6) |
| 2 | 4 (5.3) | 0 (0) | 2 (7.1) | 2 (9.5) |
| 3 | 54 (72.0) | 26 (100) | 26 (92.9) | 2 (9.5) |
|
| ||||
| PCI effect on TIMI flow | ||||
| Improved | 47 (62.7) | 21 (80.8) | 25 (89.3) | 1 (4.8) |
| Unchanged | 24 (32.0) | 5 (19.2) | 3 (10.7) | 16 (76.2) |
| Worse | 4 (5.3) | 0 (0) | 0 (0) | 4 (19.0) |
In-hospital and postdischarge clinical adverse events.
| N (%) | PCI ( | No PCI ( |
|
|---|---|---|---|
| In-hospital events: | |||
| Death | 0 (0) | 1 (0.3) | >0.9 |
| MI | 15 [ | 4 (1.2) | <0.001 |
| Repeat revascularization | 14 (18.7) | 3 (0.9) | <0.001 |
| CVA | 3 (4.0) | 2 (0.6) | 0.047 |
| In-hospital MACE | 22 (29.3) | 9 (2.8) | <0.001 |
|
| |||
| Postdischarge events: | |||
| Unstable angina hospitalization | 10 (13.3) | 19 (5.8) | 0.043 |
| Death | 0 (0) | 4 (1.2) | >0.9 |
| Recurrent MI | 15 [ | 59 (18.0) | 0.74 |
| Recurrent de novo SCAD | 5 (6.7) | 40 (12.2) | 0.22 |
| Repeat revascularization | 11 (14.7) | 10 (3.0) | <0.001 |
| CVA | 1 (1.3) | 4 (1.2) | >0.9 |
| Postdischarge MACE | 18 (24.0) | 65 (19.8) | 0.43 |
| Overall MACE | 44 (58.7) | 74 (22.6) | <0.001 |
Figure 4Kaplan–Meier event-free survival curves for PCI versus non-PCI group: (a) in-hospital major adverse events and (b) overall major adverse cardiovascular events.